Laura Alder, MD, discussed a retrospective analysis evaluating tarlatamab’s efficacy and safety in patients with SCLC and brain metastases excluded from DeLLphi-304.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.